Effects of sucralfate and sulglycotide treatment on active gastritis and Helicobacter pylori colonization of the gastric mucosa in non-ulcer dyspepsia patients.
We conducted a double-blind randomized treatment study on patients affects by non-ulcer dyspepsia in whom multiple biopsy specimens showed active gastritis. Patients were given either 3 g/day of sucralfate (n = 39) or 600 mg/day of sulglycotide (n = 50) for 6 wk, a glycopeptide isolated from pig duodenum constituents. Endoscopy was carried out at baseline and at the end of treatment. We took biopsies from the gastric body (twice) and antrum (six times) at each endoscopy in order to determine grade and extent of gastritis and Helicobacter pylori colonization. Both treatments induced a marked regression of active gastritis (sucralfate group: p less than 0.05 and p less than 0.0001, respectively, in body and in antrum; sulglycotide group: p less than 0.01 and p less than 0.001, respectively). Conversely, Helicobacter pylori colonization remained unchanged at the end of the treatments. At baseline, a close relationship was found between grade of active inflammation in each biopsy and Helicobacter pylori density. After therapy, the association was lost in each treatment group. These results suggest that there can be a remission of active gastritis in patients with non-ulcer dyspepsia even without changes in Helicobacter pylori colonization. This result can be achieved by enhancing the protective properties of the gastric mucosa.
Barbara
L
L
Istituto di Clinica Medica e Gastroenterologia, Università di Bologna, Italy.
Biasco
G
G
Capurso
L
L
Dobrilla
G
G
Lalli
A
A
Paganelli
G M
GM
Pallone
F
F
Torsoli
A
A
D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001706:Biopsy; D015169:Colony Count, Microbial; D003352:Corynebacterium / Q000254:growth & development*; D003354:Corynebacterium Infections / Q000188:drug therapy* / Q000473:pathology; D004311:Double-Blind Method; D004415:Dyspepsia / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005753:Gastric Mucosa / Q000382:microbiology*; D005756:Gastritis / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D012795:Sialoglycoproteins / Q000627:therapeutic use*; D013392:Sucralfate / Q000627:therapeutic use*
D000897:Anti-Ulcer Agents; D012795:Sialoglycoproteins; C009354:sulglicotide; D013392:Sucralfate